A new immunotherapy biotech from famed Johns Hopkins oncology researchers Bert Vogelstein and Drew Pardoll is in the works, with a sizable $153 million financing round underway.
Vogelstein, who has founded cancer detection companies like Thrive and Haystack Oncology, has been working on a “multi-year collaboration” with Pardoll to find mutation-associated neoantigens (hence MANAs) that show up on the cell surface, according to the company’s incubator, Catalio Capital Management.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.